Does hereditary hemochromatosis typically cause an early rise in transferrin saturation before ferritin increases and do menstrual periods delay iron accumulation in women?

Hereditary hemochromatosis (HH) is a genetic disorder characterized by excessive intestinal iron absorption, leading to progressive systemic iron overload. The clinical presentation and biochemical markers are heavily influenced by both genetics and physiological factors such as biological sex.

Clinical markers and early detection

The biochemical progression of iron loading typically follows a specific sequence, making certain markers more effective for early detection than others.

• Transferrin Saturation (TSAT): Research identifies elevated TSAT as the earliest biochemical indicator of hereditary hemochromatosis. TSAT measures the ratio of serum iron to total iron-binding capacity; it often reaches levels above 45% in early stages of the disease, even when total body iron stores appear normal.
• Serum Ferritin: While ferritin is an established marker of total iron stores, it is less sensitive for early-stage HH. In many cases, TSAT remains elevated for years before ferritin rises substantially. Studies like the HEIRS study have shown that relying solely on ferritin would fail to identify many individuals at risk, as ferritin elevation typically lags behind TSAT.
• Screening Sensitivity: Because TSAT can be elevated in 60-90% of individuals with the HFE C282Y mutation early in life, major guidelines (including EASL) recommend it as the primary screening tool to detect iron loading before clinical symptoms or tissue damage occur.

Impact of biological sex and menstruation

There is a clear sexual dimorphism in the phenotypic expression and timing of hereditary hemochromatosis diagnosis.

• Physiological Protection: For women, menstrual blood loss functions as a natural form of iron excretion. Losing an average of 30-80 mL of blood monthly acts as a "physiological phlebotomy," which significantly delays the accumulation of toxic levels of iron.
• Delayed Presentation: Due to this protective mechanism, women are typically diagnosed 10 to 20 years later than men. While men often present with symptoms or high iron markers in their 40s, women frequently do not show significant iron accumulation until after menopause (ages 50-60), when the iron-depleting effect of menstruation ceases.
• Clinical Phenotype: Premenopausal women often maintain lower ferritin levels and may remain asymptomatic for longer periods. Consequently, clinical guidelines often utilize different ferritin thresholds for women to account for these physiological differences.

Mechanistic explanations

The underlying pathophysiology involves the hepcidin-ferroportin axis. In HFE-related hemochromatosis, low levels of the hormone hepcidin lead to an overabundance of ferroportin (an iron-export protein) on the surface of intestinal cells. This results in continuous iron entry into the plasma, which first saturates the transport protein transferrin (raising TSAT). Only after transferrin is saturated does the excess iron get stored in tissues and reflected by rising serum ferritin levels. In women, the regular loss of hemoglobin-bound iron during menstruation creates a consistent demand for iron, which "consumes" some of this excess absorbed iron and prevents it from being stored.

Bottom line

Hereditary hemochromatosis typically presents with an early rise in transferrin saturation before ferritin increases, and menstrual blood loss acts as a natural protective mechanism that delays iron accumulation and clinical presentation in women until later in life.